PMGC Holdings Inc.ELAB
Price (close)
$4.52
Market cap
$3.7M
P/E
—
Revenue (TTM)
$2.6M
Net income
-$13.5M
Dividend yield
—
1-year total return
-99.6%
Net margin
-523.0%
Revenue growth
—
Debt / equity
0.01x
What PMGC Holdings Inc. does.
Inc. (“Northstrive Biosciences”) is a biopharmaceutical company focusing on the development and acquisition of cutting-edge
aesthetic medicines and therapeutic products. Our lead asset, EL-22, is leveraging a first-in-class engineered probiotic approach to
address obesity’s pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists.
Revenue and profit, by fiscal year.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | — | $766,277 | $1.7M | — | $590,084 |
| Net income | — | -$1.8M | -$4.3M | -$6.2M | -$7.7M |
| Free cash flow | — | — | -$4.6M | -$5.5M | -$6.4M |
More on ELAB.
- PMGC Holdings Inc. summary
- PMGC Holdings Inc. financial statements
- PMGC Holdings Inc. key metrics
- PMGC Holdings Inc. health scores and style box
- PMGC Holdings Inc. earnings
- PMGC Holdings Inc. dividends
- PMGC Holdings Inc. valuation
- PMGC Holdings Inc. ownership and insiders
- PMGC Holdings Inc. peers
Figures from PMGC Holdings Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.